Potential benefits of volumetric modulated arc therapy to reduce the incidence of ≥ grade 2 radiation pneumonitis in radiotherapy for locally advanced non-small cell lung cancer patients.

Abstract

BACKGROUND:

The use of volumetric modulated arc therapy is gradually widespread for locally advanced non-small cell lung cancer. The purpose of this study was to identify the factors that caused ≥ grade 2 radiation pneumonitis and evaluate the impact of using volumetric modulated arc therapy on the incidence of ≥ grade 2 radiation pneumonitis by comparing three-dimensional conformal radiation therapy.

METHODS:

We retrospectively evaluated 124 patients who underwent radical radiotherapy for locally advanced non-small cell lung cancer in our institution between 2008 and 2019. The following variables were analysed to detect the factors that affected ≥ grade 2 radiation pneumonitis; age, sex, the presence of interstitial lung disease, pulmonary emphysema, tumour location, stage, PTV/lung volume, lung V20Gy, total dose, concurrent chemoradiotherapy, adjuvant immune checkpoint inhibitor, radiotherapy method. Radiation pneumonitis was evaluated using the common terminology criteria for adverse events (version 5.0).

RESULTS:

A total of 84 patients underwent three-dimensional conformal radiation therapy (3D-CRT group) and 40 patients underwent volumetric modulated arc therapy (VMAT group). The cumulative incidence of ≥ grade 2 radiation pneumonitis at 12 months was significantly lower in the VMAT group than in the 3D-CRT group (25% vs. 49.1%). The use of volumetric modulated arc therapy was a significant factor for ≥ grade 2 radiation pneumonitis (HR:0.32, 95% CI: 0.15-0.65, P = 0.0017) in addition to lung V20Gy (≥ 24%, HR:5.72 (95% CI: 2.87-11.4), P < 0.0001) and total dose (≥ 70 Gy, HR:2.64 (95% CI: 1.39-5.03), P = 0.0031) even after adjustment by multivariate analysis.

CONCLUSIONS:

We identified factors associated with ≥ grade 2 radiation pneumonitis in radiotherapy for patients with locally advanced non-small cell lung cancer. Volumetric modulated arc therapy has potential benefits to reduce the risk of ≥ grade 2 radiation pneumonitis.

• Authors: Nobuki Imano, Tomoki Kimura, Daisuke Kawahara, Riku Nishioka, Wataru Fukumoto, Reo Kawano, Katsumaro Kubo, Tsuyoshi Katsuta, Yuki Takeuchi, Ikuno Nishibuchi, Yuji Murakami, Yasushi Horimasu, Takeshi Masuda, Kazunori Fujitaka, Noboru Hattori, Yasushi Nagata
• Journal: Japanese journal of clinical oncology (Jpn J Clin Oncol) Vol. 51 Issue 12 Pg. 1729-1735 (Dec 01 2021) ISSN: 1465-3621 [Electronic] England
• PMID: 34625805 (Publication Type: Journal Article)
• Copyright: © The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: [email protected].

Topics

• Carcinoma, Non-Small-Cell Lung (radiotherapy)
• Humans
• Incidence
• Lung Neoplasms (radiotherapy)
• Radiation Pneumonitis (epidemiology, etiology)
• Radiotherapy Dosage
• Radiotherapy Planning, Computer-Assisted
• Radiotherapy, Conformal (adverse effects)
• Radiotherapy, Intensity-Modulated (adverse effects)
• Retrospective Studies